Journal
JOURNAL OF HEALTH ECONOMICS
Volume 31, Issue 1, Pages 158-168Publisher
ELSEVIER
DOI: 10.1016/j.jhealeco.2011.09.004
Keywords
Willingness to pay; WTP; Contingent valuation; Sensitivity to scale; Validity; QALY
Funding
- Astra-Zeneca
- GlaxoSmithKline
- Janssen-Cilag
- Merck
- Pfizer BV
Ask authors/readers for more resources
Estimates of WTP per QALY can be taken as an indication of the monetary value of health gains, which may carry information regarding the appropriate height of the cost-effectiveness threshold. Given the farreaching consequences choosing a particular threshold, and thus the potential relevance of WTP per QALY estimates, it is important to address the validity of these estimates. This study addresses this issue. Our findings offer little support to the validity of WTP per QALY estimates obtained in this study. Implications for general WIT per QALY estimates and further research are discussed. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available